Defeat drug resistance and eradicate cancer cells!

Breast cancer, the number one health killer for women, ranks first among women in the world in terms of morbidity and mortality

At present, the treatment of drug-resistant ERα-positive breast cancer is still the main clinical challenge, and most patients with metastatic cancer will relapse within 7 years

Recently, the clinical treatment research of metastatic ERα-positive breast cancer has made significant new progress

First of all, this study conducted an in vitro test on ErSO.

Subsequently, the researchers conducted in vivo experiments on ErSO in several preclinical orthotopic and metastatic mouse models that carry xenografts of different human breast cancer cell lines or patient-derived breast tumors

The researchers also tested the ability of ErSO to induce regression of mutant ERα tumors.

Next, the researchers assessed whether ErSO caused a lasting response in the TYS-mouse model

The effect of ErSO on four tumor xenograft mouse models

To evaluate the efficacy of ErSO on heterogeneous, mutant ERα human breast tumors, the researchers used a hormone-independent PDX model called ST941/HI

Since tumors that have spread to other parts of the body are responsible for the death of most breast cancer patients, this study also explored the ability of ErSO to eradicate tumors at the main metastatic sites

ErSO can quickly destroy most lung, bone and liver metastases, and sharply shrink brain metastases

The new small molecule drug ErSO in this study can not only induce tumor regression, prevent cancer recurrence and metastasis, but also inhibit the emergence of tumor drug resistance

Reference materials:

[1]https://stm.